Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054477 · ClinicalTrials.gov registry record · Phase 1
Study of ALE.C04 in Patients With Head and Neck Cancer
A Phase 1 study, sponsored by Alentis Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT06054477 is a Phase 1 study that was terminated before completion, run by Alentis Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT06054477, a Phase 1 study, was terminated before completion, sponsored by Alentis Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 in combination with pembrolizumab in patients with Head and Neck Cancer.
Interventions
- DRUG Pembrolizumab
- DRUG ALE.C04
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054477
The ClinicalTrials.gov registry entry for NCT06054477 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alentis Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06054477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06054477 about?
NCT06054477 is a clinical study titled "Study of ALE.C04 in Patients With Head and Neck Cancer". The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 i...
What is the current status of trial NCT06054477?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-10-30. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT06054477?
The interventions under investigation include: Pembrolizumab (DRUG), ALE.C04 (DRUG).
Who is sponsoring clinical trial NCT06054477?
This trial is sponsored by Alentis Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.